GURUFOCUS.COM » STOCK LIST » USA » NAS » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Beneish M-Score
Switch to:

Atara Biotherapeutics Beneish M-Score

: 15.25 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 15.25 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Atara Biotherapeutics's Beneish M-Score or its related term are showing as below:

ATRA' s Beneish M-Score Range Over the Past 10 Years
Min: 15.25   Med: 15.25   Max: 15.25
Current: 15.25

During the past 10 years, the highest Beneish M-Score of Atara Biotherapeutics was 15.25. The lowest was 15.25. And the median was 15.25.


Atara Biotherapeutics Beneish M-Score Historical Data

The historical data trend for Atara Biotherapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 15.25

Competitive Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Atara Biotherapeutics Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Beneish M-Score falls into.



Atara Biotherapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Atara Biotherapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.0102+0.528 * 1+0.404 * 37.9069+0.892 * 6.7855+0.115 * 0.5041
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1848+4.679 * -0.2783-0.327 * 1.6397
=15.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Total Receivables was $0.67 Mil.
Revenue was 7.314 + 7.548 + 5.37 + 3.87 = $24.10 Mil.
Gross Profit was 7.314 + 7.548 + 5.37 + 3.87 = $24.10 Mil.
Total Current Assets was $314.39 Mil.
Total Assets was $397.28 Mil.
Property, Plant and Equipment(Net PPE) was $28.04 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.71 Mil.
Selling, General, & Admin. Expense(SGA) was $81.63 Mil.
Total Current Liabilities was $101.56 Mil.
Long-Term Debt & Capital Lease Obligation was $17.45 Mil.
Net Income was -88.105 + -93.349 + -84.664 + -83.793 = $-349.91 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -84.529 + -34.269 + -58.978 + -61.577 = $-239.35 Mil.
Total Receivables was $9.61 Mil.
Revenue was 3.552 + 0 + 0 + 0 = $3.55 Mil.
Gross Profit was 3.552 + 0 + 0 + 0 = $3.55 Mil.
Total Current Assets was $464.31 Mil.
Total Assets was $529.64 Mil.
Property, Plant and Equipment(Net PPE) was $63.40 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.61 Mil.
Selling, General, & Admin. Expense(SGA) was $65.10 Mil.
Total Current Liabilities was $84.19 Mil.
Long-Term Debt & Capital Lease Obligation was $12.57 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.668 / 24.102) / (9.61 / 3.552)
=0.02771554 / 2.70551802
=0.0102

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.552 / 3.552) / (24.102 / 24.102)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (314.389 + 28.042) / 397.28) / (1 - (464.307 + 63.401) / 529.637)
=0.13806132 / 0.00364212
=37.9069

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=24.102 / 3.552
=6.7855

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(8.605 / (8.605 + 63.401)) / (8.714 / (8.714 + 28.042))
=0.11950393 / 0.23707694
=0.5041

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(81.634 / 24.102) / (65.102 / 3.552)
=3.38702182 / 18.32826577
=0.1848

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((17.453 + 101.562) / 397.28) / ((12.569 + 84.194) / 529.637)
=0.29957461 / 0.18269683
=1.6397

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-349.911 - 0 - -239.353) / 397.28
=-0.2783

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Atara Biotherapeutics has a M-score of 15.25 signals that the company is likely to be a manipulator.


Atara Biotherapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Atara Biotherapeutics logo
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Executives
Yarema Kristin officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080
Murugan Amar officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080
Dupont Jakob officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Touchon Pascal director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Koppikar Utpal officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Mallik Ameet director C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102
Renaud Ronald C Jr director C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109
Seidenberg Beth C director
Heiden William K director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Dobmeier Eric director C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021
Roncarolo Maria Grazia director C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Gallagher Carol Giltner director C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005
Fust Matthew K director C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Baynes Roy D. director C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Berger Dietmar officer: Global Head of R&D C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080

Atara Biotherapeutics Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)